



MICROALBUNURIA IN HYPERTENSIVE PATIENTS ATTENDING GENERAL MEDICINE OPD AT PRAKASH INSTITUTE OF MEDICAL SCIENCE & RESEARCH URUN-ISLAMPUR, MAHARASHTRA, INDIA.

Dr. Mahendra Joshi¹, Dr. Mrs. Shalaka Abhijeet Tagare²

¹ Professor and HOD Dept. of Medicine Prakash Institute of Medical Science & Research Urun-Islampur, Maharashtra, India.

² Assistant Professor Dept. of Medicine Prakash Institute of Medical Science & Research Urun-Islampur, Maharashtra, India.

Conflicts of Interest: Nil

ABSTRACT:

INTRODUCTION: Hypertension is a major public health problem all over the world and in India the prevalence of hypertension is around 25% in urban and 10-15% in rural, adult population while in the West it is 30%. Albumin is recognized as the earliest sign of vascular damage in both the kidney and the heart and albuminuria and its association with kidney disease. Proteinuria and microalbuminuria are independent predictors of cardiovascular morbidity and mortality in patients with hypertension. Kidney disease is linked to heart disease and the presence of microalbuminuria which can be defined as urinary albumin excretion of 30 - 300 mg / day, or 20-200 µg/min is a predictor of worse outcomes for both kidney and heart patients. Microalbuminuria does not directly cause cardiovascular diseases but it serves as a marker for identifying those who may be at increased risk of cardiovascular episodes. Albuminuria might reflect a general vascular dysfunction and leakage of albumin and other plasma macromolecules like low density lipoproteins which lead to inflammatory responses and start the atherosclerosis process.

MATERIAL AND METHODS: This is an observational, cross-sectional study done in hypertensive patients. Blood pressure monitoring was carried out according to the WHO guidelines. The values reported were the average of three consecutive measurements taken over a 15-minute period. All routine biochemical tests and microalbuminuria tests were performed by the laboratory. All patients determined to have microalbuminuria who matched the inclusion criteria were enrolled for a 1-year follow-up. Statistical analysis was performed by using standard methods to calculate rates and proportions.

RESULTS: A total of 157 patients were included in the study. Out of which 96 (61%) were male and 61 (39%) were female. Retinopathy was observed in 21 (13%) cases and Left ventricular hypertrophy was seen in 67 (43%) patients. Microalbuminuria was observed in 92 (59%) cases. Systolic Blood pressure and diastolic blood pressure in microalbuminuric cases was 163.5 ± 19.2 , and 101.6 ± 8.9 respectively, while in normal patients it was 144.3 ± 17.2 and 85.4 ± 11.2 . There was significant difference observed in microalbuminuric and normal cases in terms of serum urea, serum creatinine, serum uric acid and serum cholesterol. Urinary albumin excretion was significantly higher in microalbuminuric cases as compared to normal patients.

CONCLUSION: The prevalence of microalbuminuria among patients with essential hypertension was 59% and was associated with higher blood pressure values. . Prevalence of microalbuminuria in

hypertensive patients suggests that screening for microalbuminuria is essential for intervention and prevention of further complications.

Introduction

Hypertension is a major public health problem all over the world and in India the prevalence of hypertension is around 25% in urban and 10-15% in rural, adult population while in the West it is 30%.ⁱ Hypertension in the diabetic patients markedly increases the risk and accelerates the course of cardiac disease, peripheral vascular disease, stroke, retinopathy, and nephropathy.ⁱⁱ Albumin is recognized as the earliest sign of vascular damage in both the kidney and the heart and albuminuria and its association with kidney disease has been recognized for more than 200 years.ⁱⁱⁱ Several studies have shown that proteinuria and microalbuminuria are independent predictors of cardiovascular morbidity and mortality in patients with hypertension. Kidney disease is linked to heart disease and the presence of microalbuminuria which can be defined as urinary albumin excretion of 30 - 300 mg / day, or 20-200 µg/min is a predictor of worse outcomes for both kidney and heart patients. In America, approximately 6% of men and 9.7% of woman have microalbuminuria.^{iv} Microalbuminuria does not directly cause cardiovascular diseases but it serves as a marker for identifying those who may be at increased risk of cardiovascular episodes. Microalbuminuria is caused by glomerular capillary injury and so it may be a marker for diffuse endothelial dysfunction.^v In patients with essential hypertension, the combined presence of microalbuminuria and hyperlipidaemia is frequently seen. There is possibility for the association between microalbuminuria and hyperlipidaemia because of abnormal intake of lipids with the diet.

Albuminuria might reflect a general vascular dysfunction and leakage of albumin and other plasma macromolecules like low density lipoproteins which lead to inflammatory responses and start the atherosclerosis process.^{vi} Two mechanisms have been proposed for the urinary albumin excretion (UAE) in some of the patients with essential hypertension

first, increased glomerular hydrostatic pressure and second, increased permeability of the glomerular basement membrane.^{vii}

MATERIAL AND METHODS

This is an observational, cross-sectional study done in hypertensive patients. The present study was carried out at Prakash Institute of Medical Science & Research Urun-Islampur. The Out Patient Clinic of Department of General Medicine. Patients who recorded a high blood pressure based on JNC 8 (Joint National Commission 8) criteria during three consecutive visits to the outpatient clinic and who had a creatinine clearance greater than 80 ml/min/1.73 m², were included in the study. Age group included in the study was 25 to 70 years.

Patients with Diabetes Mellitus, secondary hypertension, BP more than 210/110 mm Hg, unstable hypertension and hyperkalaemia were excluded from the study. Pregnant ladies were excluded from the study. Patients with clinical or laboratory evidence of hepatic, renal, or any other major disease and renal cause of hypertension were also excluded from the study. Patients who had been treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists (ARBs) during at least the 2 weeks were excluded.

Blood pressure monitoring was carried out according to the WHO guidelines.^{viii} Blood pressure was measured after five minutes of rest using a mercury sphygmomanometer, the values reported were the average of three consecutive measurements taken over a 15-minute period. Mean arterial pressure was calculated adding diastolic blood pressure with one-third of pulse pressure. Demographic data, age, sex, weight, associated cardiovascular disease, albuminuria, and clinical parameters were all recorded. Patients' visits were scheduled at the beginning, at 6 months, and at the end of the study i.e. after 12 months. All routine biochemical tests and microalbuminuria tests were performed by the laboratory. All patients determined to have

microalbuminuria who matched the inclusion criteria were enrolled for a 1-year follow-up.

Statistical analysis was performed by using standard methods to calculate rates and proportions; Z test was used for analysing the differences between the variables. A two-tail P value was used for calculating statistical significance. A P value of < 0.01 was considered as statistically significant.

RESULTS

A total of 157 patients were included in the study. Out of which 96 (61%) were male and 61 (39%) were female. Retinopathy was observed in 21 (13%) cases and Left ventricular hypertrophy was seen in 67 (43%) patients. Microalbuminuria was observed in 92 (59%) cases.

Table 1:

Total patients (n)	157	percentage
Male	96	61%
Female	61	39%
Retinopathy		
Present	21	13%
Absent	136	87%
Left ventricular Hypertrophy (LVH)		
Present	67	43%
Absent	90	57%
Microalbuminuria		
Present	92	59%
Absent	65	41%

Table 2: Parameters in microalbuminuric and normal patients

Parameters	Microalbuminuric cases (n= 92)		Normal albumin level (n=65)		P value	Significance
	Mean	SD	Mean	SD		
Duration of Hypertension	48.4	11.6	31.5	12.9	P < 0.0001	Significant
Systolic Blood pressure (mmHg)	163.5	19.2	144.3	17.2	P < 0.0001	Significant
Diastolic Blood pressure (mmHg)	101.6	8.9	85.4	11.2	P < 0.0001	Significant
BMI	29.5	2.8	26.4	2.1	P < 0.0001	Significant
Serum Urea	35.4	8.1	34.2	6.9	P < 0.0001	Significant
Serum Creatinine	0.92	0.18	0.81	0.13	P < 0.0001	Significant
Serum uric acid	4.3	0.9	4.1	0.7	P = 0.1359	Not Significant
serum Cholesterol	193.4	38.4	177.5	31.4	P < 0.0001	Significant
urinary albumin excretion (mg/ 24 hours)	30.5	5.1	18.4	0.8	P < 0.0001	Significant

Duration of hypertension in Microalbuminuric cases was 48.4 ± 11.6 while in normal patients it was 31.5 ± 12.9 , it was highly significant. Systolic Blood pressure and diastolic blood pressure in microalbuminuric cases was 163.5 ± 19.2 , and 101.6 ± 8.9 respectively, while in normal patients it was 144.3 ± 17.2 and 85.4 ± 11.2 both results were highly significant. Body mass index (BMI) in microalbuminuric cases was 29.5 ± 2.8 and in normal cases it was 26.5 ± 2.1 . There was significant difference observed in microalbuminuric and normal cases in terms of serum urea, serum creatinine, serum uric acid and serum cholesterol. Urinary albumin excretion was significantly higher in microalbuminuric cases as compared to normal patients

DISCUSSION

Present study was conducted at Prakash Institute of Medical Science & Research Urun-Islampur in the department of General Medicine. Microalbuminuria can occur frequently in the general population, even in subjects without hypertension. There is evidence that, in diabetes, already modestly increased levels of albumin excretion are associated with an increased glomerular filtration rate (GFR) in patients with essential hypertension and in non-diabetic non-hypertensive subjects. Microalbuminuria is associated with an enhanced risk for cardiovascular morbidity and mortality, with an enhanced risk for progressive renal failure in hypertensive and in non-diabetic, non-hypertensive subjects^{ix}. Therefore screening for microalbuminuria was found to an excellent tool, either alone or in combination with screening for hypertension and hypercholesterolemia^x.

Renal dysfunction is a common clinical condition in patients with hypertension and is associated with an increased risk for CVEs as well as progression to end-stage renal disease^{xi, xii}. Studies have shown that the presence of microalbuminuria also increases the relative risk of an adverse cardiovascular episode like hypercholesterolemia^{xiii}.

In our study it was found that microalbuminuria in our study was 59%. Similar findings was shown by Poudel B et al in their study percentage

of microalbuminuria in essential hypertensive patients was 51.88%^{xiv}. The prevalence of microalbuminuria and it may vary from 15 to 100% may be due to differences in age, race, severity of hypertension, and coexistent renal disease in the study populations^{xv}. Microalbuminuria should be tested routinely in all hypertensive patients as its appearance, progression to proteinuria can be correlated with a higher or lower risk of coronary heart disease, stroke, or peripheral vascular disease. That means urinary albumin excretion is a marker of cardiovascular risk, and also a marker of treatment efficacy. In a study by *Bramlage P^{xvi}* et al showed prevalence of 21.2% of microalbuminuria in patients with hypertension. *Hillege HL* et al. found that microalbuminuria is also common in a nondiabetic, nonhypertensive population, and an indicator of cardiovascular risk factors and cardiovascular morbidity^{xvii}.

In our study there was a significant difference in the level of serum urea, creatinine, uric acid and cholesterol in microalbuminuria patients and normal individuals. In a study by Marudhaiveeran et al. found significant difference between urinary albumin excretion but he did not found significance in serum urea, creatinine, uric acid and cholesterol and according to them up to 80% of hypertensive patients show a concomitant cardiovascular risk factor^{xviii}.

The risk factors associated with microalbuminuria was found to be poor blood glucose control and hypertension and excretion of even small amounts of albumin in the urine may portend serious future events, such as elevation of systemic arterial pressure, cardiovascular disease and progressive renal dysfunction^{xix}. Thus microalbuminuria is a sensitive marker for damage induced by diabetes^{xx}. Proteinuria in patients represents a predictor of progressive renal impairment in all form of glomerulonephritis^{xxi}. Some studies stated that the presence of microalbuminuria in early stage of essential hypertension can be taken as an important predictor for progression of renal disease^{xxii}. Microalbuminuria reflects vascular damage and appears to be a marker of early arterial disease^{xxiii}.

CONCLUSION

The prevalence of microalbuminuria among patients with essential hypertension was 59% and was associated with higher blood pressure values. Available tests for screening microalbuminuria are sensitive, reliable and accessible. Prevalence of microalbuminuria in hypertensive patients suggests that screening for microalbuminuria is essential for intervention and prevention of further complications like end stage renal disease and cardiovascular disease and it is essential to screen for early nephropathy by testing microalbuminuria in hypertensive patients prevent or halt the earliest stages of damage

REFERENCES

1. ⁱEpidemiology of hypertension. JAPI 2013;61:12-3.
2. ⁱⁱEpstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992 May; 19(5):403-18.
3. ⁱⁱⁱGlassock RJ. Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams? J Am Soc Nephrol. 2006 Dec; 17(12):3276-8.
4. ^{iv}Wrone EM, Carnethon MR, Palaniappan L, Fortmann SP, Third National Health and Nutrition Examination Survey. Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003 Mar; 41(3):580-7.
5. ^vRuggenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004 Nov 4; 351(19):1941-51.
6. ^{vi}Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989 Apr; 32(4):219-26.
7. ^{vii}Bhattarai M, Bhandari B. Microalbuminuria in hypertension: A review. J Nobel Med Coll 2012;2:1-10.
8. ^{viii}1999 World Health Organization International Society of Hypertension Guidelines for the management of Hypertension. J Hypertens. 1999; 17: 151–183
9. ^{ix}Paul E. de Jong, Hans L. Hillege, Sara Joan Pinto-Sietsma, Dick de Zeeuw; Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?, *Nephrology Dialysis Transplantation*, Volume 18, Issue 1, 1 January 2003, Pages 10–13
10. ^xScheid DC, McCarthy LH, Lawler FH et al. Screening for microalbuminuria to prevent nephropathy in patients with diabetes. J Fam Pract 2001; 50:661–668
11. ^{xi}Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006;17:2034-47.
12. ^{xii}Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
13. ^{xiii}Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000;35:898-903.
14. ^{xiv}Bibek Poudel, Binod Kumar Yadav, Ashwini Kumar Nepal, Bharat Jha, Kanak Bahadur Raut. Prevalence and Association of Microalbuminuria in Essential Hypertensive Patients. N Am J Med Sci. 2012 Aug; 4(8): 331–335. doi: 10.4103/1947-2714.99501
15. ^{xv}Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri G, Palla L, et al. Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild hypertension. Am J Hypertens 1989;2:259-61.

16. ^{xvi}Bramlage P, Pittrow D, Lehnert H, Höfler M, Kirch W, Ritz E, Wittchen HU. Frequency of albuminuria in primary care: a cross-sectional study. *Eur J Cardiovasc Prev Rehabil.* 2007 Feb; 14(1):107-13.
17. ^{xvii}Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijs HJ, Van Gilst WH, De Zeeuw D, De Jong PE, Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. *J Intern Med.* 2001 Jun; 249(6):519-26.
18. ^{xviii}Marudhaiveeran GM, Radhakrishnan S, Alphonse F. Prevalence of microalbuminuria among patients with essential hypertension. *Trop J Med Res* 2014;17:76-80
19. ^{xix}Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation.* 2002 Oct 1; 106(14):1777-82.
20. ^{xx}Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE, PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. *Kidney Int Suppl.* 2004 Nov; (92):S18-21.
21. ^{xxi}Maschio G, Oldrizzi L, Rugiu C, Valvo E, Lupo A, Loschiavo C, Tessitore N, Fabris A, Gammara L, Panzetta G. Factors affecting progression of renal failure in patients on long-term dietary protein restriction. *Kidney Int Suppl.* 1987 Oct; 22():S49-52.
22. ^{xxii}Pruijm MT, Madeleine G, Riesen WF, Burnier M, Bovet P. Prevalence of microalbuminuria in the general population of Seychelles and strong association with diabetes and hypertension independent of renal markers. *J Hypertens.* 2008 May; 26(5):871-7.
23. ^{xxiii}Pontremoli R, Leoncini G, Viazzi F, Parodi D, Vaccaro V, Falqui V, et al. Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension. *J Am Soc Nephrol* 2005;16(Suppl 1):S39-41.